US equities |
META $624.78 ▼-0.92% TSLA $405.80 ▲+3.62% MU $924.48 ▲+2.30% NVDA $217.86 ▲+0.86% SPCX $149.57 ▲+1.82% AMD $556.42 ▲+4.73% SNDK $1,288.90 ▲+2.65% INTC $93.19 ▲+3.01%
FinancialContent

Kairos Pharma, Ltd. Common Stock (NY:KAPA)

0.5500 +0.0139 (+2.59%)
Delayed Quote Updated: 11:19 AM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kairos Pharma, Ltd. Common Stock

< Previous 1 2 3 4 5 6 Next >
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Publishes Findings on Overcoming NSCLC Drug Resistance
Via Investor Brand Network
News headline image
Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Presents Positive Preclinical Data on KROS 101 and KROS 401 at AACR IO Conference
Via Investor Brand Network
News headline image
Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds’ Potential as Therapeutics for Melanoma and Glioblastoma
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Secures $600K in Funding for ENV205 Development
Via Investor Brand Network
News headline image
Kairos Pharma Announces New Department of Defense Funding for Research of ENV205
From Kairos Pharma, Ltd
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Adds Huntsman Cancer Institute to Phase 2 Trial for Prostate Cancer Therapy
Via Investor Brand Network
News headline image
Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Highlights Preclinical Data on GITR Agonist KROS 101 at AACR-JCA Conference
Via Investor Brand Network
News headline image
Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound’s Potential as a Therapeutic for Melanoma and Glioblastoma
From Kairos Pharma, Ltd.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why ↗
Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts. 
Via Stocktwits
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present at AACR-JCA Joint Conference on Innovative Cancer Therapy
Via Investor Brand Network
News headline image
Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024
From Kairos Pharma, Ltd
Via Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Highlights 2024 Milestones and 2025 Clinical Outlook
Via Investor Brand Network
Topics Intellectual Property
News headline image
Kairos, OS Therapies, AEON See Highest Weekly Spike In Retail Following Among Biotechs: Here's Why ↗
Cancer treatments, FDA breakthroughs, and other developments fueled a sharp spike in interest for these biotech players, as investors bet on promising clinical data and strategic moves. 
Via Stocktwits
News headline image
Kairos Pharma Provides Business Update and Outlook into 2025
From Kairos Pharma, Ltd
Via Business Wire
News headline image
US Stocks Mixed; Nasdaq Down Over 1% ↗
 
Via Benzinga
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) to Present at Lytham Partners Investor Healthcare Summit
Via Investor Brand Network
News headline image
Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – EF Hutton Provided ‘Buy’ Rating, $9.00 Price Target in Kairos Pharma, Ltd. (NYSE: KAPA) Recent Research Report
Via Investor Brand Network
BioMedNewsBreaks — Kairos Pharma, Ltd. (NYSE: KAPA) Receives ‘Buy’ Recommendation, $12.00 Price Target in Rodman & Renshaw Research Report
Via Investor Brand Network
News headline image
Kairos Pharma to Participate in The Microcap Conference in January 2025
Via ACCESSWIRE
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present Growth Strategy at The Microcap Conference 2025
Via Investor Brand Network
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Expands Phase 2 Trial of ENV105 to City of Hope for Prostate Cancer Therapy
Via Investor Brand Network
News headline image
Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial
From Kairos Pharma, Ltd
Via Business Wire
InvestorkNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Engages IBN for Corporate Communications Expertise
Via Investor Brand Network
Topics Intellectual Property
< Previous 1 2 3 4 5 6 Next >